Open AccessTreatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
Author(s) -
Stefano Molica,
Paolo Sportoletti,
Nicola Di Renzo,
Pellegrino Musto,
Fabrizio Pane,
F. Di Raimondo
Publication year - 2021
Publication title -
mediterranean journal of hematology and infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 31
ISSN - 2035-3006
DOI - 10.4084/mjhid.2021.042
Subject(s) - medicine , pandemic , rituximab , covid-19 , venetoclax , chronic lymphocytic leukemia , refractory (planetary science) , leukemia , immunology , virology , lymphoma , disease , infectious disease (medical specialty) , physics , outbreak , astrobiology
With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies (1-2). Given the multiple immune defects characterizing chronic lymphocytic leukaemia (CLL), it is considered that patients with this form of leukemia have a high-risk of suffering severe forms of COVID-19 (3-4).